Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report.
HDAC inhibitor
PTCL
allogenic stem cell transplantation
belinostat
complete response
nTFHL‐AI
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
27
04
2023
revised:
03
06
2023
accepted:
15
06
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
This case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T-cell lymphomas, for which effective therapies are still scarce. Peripheral T-cell lymphomas have an aggressive disease course associated with poor outcomes. We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T-cell lymphoma (angioimmunoblastic-type [nTFHL-AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy. The complete hematologic response achieved has lasted more than 2 years.
Identifiants
pubmed: 37361652
doi: 10.1002/ccr3.7623
pii: CCR37623
pmc: PMC10290197
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e7623Informations de copyright
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Vincent Camus received honoraria from IDEOGEN AG (Switzerland). The other authors declare no conflict of interest regarding this manuscript.
Références
Transl Cancer Res. 2020 Nov;9(11):7259-7283
pubmed: 35117329
J Oncol Pract. 2019 Mar;15(3):137-143
pubmed: 30861367
Leuk Lymphoma. 2020 Aug;61(8):2003-2007
pubmed: 32336176
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
Clin Cancer Res. 2015 Jun 15;21(12):2666-70
pubmed: 25802282
Bioinformatics. 2018 Nov 1;34(21):3771-3772
pubmed: 29790900
Cancers (Basel). 2022 May 08;14(9):
pubmed: 35565460
Transplantation. 2002 Jul 15;74(1):60-6
pubmed: 12134100
Blood Rev. 2007 Jul;21(4):201-16
pubmed: 17512649
Blood. 2014 Apr 24;123(17):2636-44
pubmed: 24615779
Haematologica. 2020 Jun;105(6):1582-1592
pubmed: 31488561
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Br J Haematol. 2015 Mar;168(6):811-9
pubmed: 25404094
Curr Opin Oncol. 2018 Sep;30(5):277-284
pubmed: 30028743
Blood. 2011 Jun 2;117(22):5827-34
pubmed: 21355097
J Clin Oncol. 2013 Jan 10;31(2):240-6
pubmed: 22869878
Cancer. 2019 May 1;125(9):1507-1517
pubmed: 30694529
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
pubmed: 16955068
J Clin Oncol. 2011 Mar 20;29(9):1182-9
pubmed: 21245435
Blood. 2021 Jul 22;138(3):213-220
pubmed: 34292324
Leukemia. 2011 Jul;25(7):1147-52
pubmed: 21494260
Curr Oncol Rep. 2008 Sep;10(5):404-11
pubmed: 18706268
Blood. 1994 Oct 15;84(8):2640-8
pubmed: 7919378
J Hematol Oncol. 2013 Sep 10;6:69
pubmed: 24020452
Ther Adv Hematol. 2011 Jun;2(3):161-73
pubmed: 23556087
J Clin Oncol. 2015 Aug 10;33(23):2492-9
pubmed: 26101246